The realistic timeline: most users report nothing visible until weeks 4-6
In SURPASS-4, tirzepatide 5, 10 and 15 mg reduced triglycerides, low-density lipoprotein cholesterol (LDL-C) and total cholesterol, and increased HDL-C, compared with baseline and the active comparator in the high CV risk population (82% on lipid-lowering therapy at baseline, which was continued throughout the study) [11]
Wegovy Effectiveness Wegovy results from real patients Compare clinical trial outcomes across specific treatment pathways and weight-management goals
10.1056/NEJMoa1509225 77 PsichasA.SleethM
From mental health to musculoskeletal and cardiovascular conditions, weight can influence how a person feels, moves and functions every day
The New England Journal of Medicine: Tirzepatide Once Weekly for the Treatment of Obesity PubMed Central: Adverse Events Related to Tirzepatide Mayo Clinic: Tirzepatide (Subcutaneous Route) Cleveland Clinic: Tirzepatide Injection Eli Lilly for Medical Professionals: Does Mounjaro (tirzepatide) cause medullary thyroid carcinoma (MTC) or C cell hyperplasia